Written by Jane Aubrey
In a stark reminder of the immense logistical complexities surrounding radiopharmaceuticals, the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) rejecting ITM Isotope Technologies Munich SE’s New Drug Application for its highly anticipated cancer therapy, ITM-11.
The decision, announced on August 10, 2026, halts the momentum of a drug that was widely expected to become a major competitor in the rapidly expanding market for targeted radioligand therapies.
ITM-11 (177Lu-edotreotide) is an investigational agent designed for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The therapy utilizes a targeting molecule that binds specifically to somatostatin receptors, which are overexpressed on the surface of these specific tumor cells. Once bound, the drug delivers a localized dose of radiation (Lutetium-177) directly to the tumor, destroying the cancer cells while minimizing damage to surrounding healthy tissue.
The clinical data supporting ITM-11 was robust. The NDA was based on the pivotal Phase 3 COMPETE trial, which demonstrated that ITM-11 provided a clinically and statistically significant improvement in progression-free survival (PFS) compared to the standard-of-care targeted therapy, everolimus, in patients with inoperable, progressive Grade 1 or Grade 2 GEP-NETs.
Crucially, the FDA’s rejection was not based on this clinical data. In its official press release, ITM confirmed that the FDA “did not identify any concerns regarding the clinical or nonclinical data package or safety profile of ITM-11,” nor did the agency request any additional clinical trials.
Instead, the CRL cited issues strictly related to Chemistry, Manufacturing, and Controls (CMC) and items related to the inspection of a third-party commercial manufacturing facility.
This rejection highlights the Achilles’ heel of the radiopharmaceutical renaissance. Unlike traditional small-molecule drugs or even complex biologics, radiopharmaceuticals involve the handling, synthesis, and rapid distribution of radioactive isotopes with incredibly short half-lives. Lutetium-177, the isotope used in ITM-11, has a half-life of just 6.6 days. This means the drug must be manufactured “just-in-time” and shipped globally with zero margin for error in the supply chain.
The FDA’s scrutiny of CMC processes for radiopharmaceuticals is notoriously rigorous, as any deviation in manufacturing can result in a product that is either sub-therapeutic by the time it reaches the patient or, conversely, poses a radiation safety hazard. The reliance on third-party commercial facilities further complicates the regulatory pathway, as the sponsor company is ultimately held responsible for the compliance of its entire contract manufacturing network.
Dr. Andrew Cavey, CEO of ITM, stated that the company’s “confidence in ITM-11’s therapeutic potential has not wavered,” and confirmed that ITM intends to work closely with the FDA and its partners to address the facility inspection items and resubmit the NDA.
While the clinical efficacy of ITM-11 remains unchallenged, this regulatory delay provides a significant commercial advantage to competitors already established in the GEP-NET radiopharmaceutical space, notably Novartis with its approved therapy, Lutathera. For ITM, the path forward requires a flawless execution of supply chain and manufacturing remediation to satisfy an FDA that is increasingly uncompromising on the logistics of radioactive medicine.
